Related Experiment Videos

Clopidogrel: who, when, and how?

Christopher P Cannon1

  • 1Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Reviews in Cardiovascular Medicine
|October 17, 2007
PubMed

Insights

Clopidogrel plus aspirin significantly reduces adverse events in acute coronary syndromes. Early treatment, especially before percutaneous coronary intervention (PCI), and up to one year of therapy improve patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Acute coronary syndromes (ACS) are a major cause of cardiovascular morbidity and mortality.
  • Clopidogrel is an antiplatelet medication used in ACS management.
  • Uncertainties remain regarding optimal clopidogrel use in clinical practice.

Purpose of the Study:

  • To review clinical trial data on clopidogrel use in patients with ACS.
  • To address questions regarding patient selection, timing, dosage, and duration of clopidogrel therapy.

Main Methods:

  • Analysis of results from completed randomized controlled trials assessing clopidogrel in ACS patients.
  • Evaluation of treatment strategies including loading dose, timing relative to percutaneous coronary intervention (PCI), and duration of therapy.

Main Results:

  • Clopidogrel plus aspirin demonstrated a reduction in the composite endpoint of death, myocardial infarction, or stroke compared to aspirin alone in ACS patients.
  • Early initiation of clopidogrel (over 6 hours before PCI) was linked to decreased risk of death and recurrent ischemic events.
  • A 600-mg loading dose of clopidogrel before PCI showed proven benefits.
  • Long-term treatment with clopidogrel for up to 1 year post-PCI is recommended by guidelines.

Conclusions:

  • Clopidogrel in combination with aspirin offers significant benefits for ACS patients.
  • Optimal timing (early, pre-PCI) and duration (up to 1 year) of clopidogrel therapy are crucial for maximizing patient outcomes.
  • Evidence supports the use of a 600-mg loading dose prior to PCI.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...